


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Canceled)

2. (Canceled)

3. (Presently Amended) ~~The agent of claim 2, wherein the macrolide compound is~~ An agent suitable for treating retinopathy comprising a tricyclo compound of formula (I) of the following formula



wherein adjacent pairs of R<sup>1</sup> and R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup>, and R<sup>5</sup> and R<sup>6</sup> each independently

- a) consist of two adjacent hydrogen atoms, wherein R<sup>2</sup> is optionally alkyl, or
- b) form another bond optionally between carbon atoms binding with the members of said pairs;

R<sup>7</sup> is hydrogen atom, hydroxy, protected hydroxy, or alkyloxy, or optionally form oxo with R<sup>1</sup>;

R<sup>8</sup> and R<sup>9</sup> are each independently ~~show~~ a hydrogen atom or hydroxy;

Cont  
A14

$R^{10}$  is hydrogen atom, alkyl, alkyl substituted by one or more hydroxy, alkenyl, alkenyl substituted by one or more hydroxy or alkyl substituted by oxo;

X is oxo, (hydrogen atom, hydroxy), (hydrogen atom, hydrogen atom), or a group of the formula  $-\text{CH}_2\text{O}-$ ;

Y is oxo, (hydrogen atom, hydroxyl), (hydrogen atom, hydrogen atom), or a group of the formula  $\text{N}-\text{NR}^{11}\text{R}^{12}$  or  $\text{N}-\text{OR}^{13}$ ;

$R^{11}$  and  $R^{12}$  are each independently ~~show~~ a hydrogen atom, alkyl, aryl or tosyl;


$R^{13}$ ,  $R^{14}$ ,  $R^{15}$ ,  $R^{16}$ ,  $R^{17}$ ,  $R^{18}$ ,  $R^{19}$ ,  $R^{22}$  and  $R^{23}$  are each independently ~~show~~ a hydrogen atom or alkyl;

$R^{24}$  is a ring that is optionally substituted and optionally contain one or more hetero atom(s); and

n is 1 or 2,

wherein Y,  $R^{10}$  and  $R^{23}$  are optionally ~~show~~, together with the carbon atom they bind with, a saturated or unsaturated 5 or 6-membered heterocyclic group containing nitrogen atom, sulfur atom and/or oxygen atom, the heterocyclic group being optionally substituted by one or more group(s) selected from the group consisting of alkyl, hydroxy, alkyloxy, benzyl, a group of the formula  $-\text{CH}_2\text{Se}(\text{C}_6\text{H}_5)$ , and alkyl substituted by one or more hydroxy, or a pharmaceutically acceptable salt thereof

4. (Presently Amended) The agent of ~~claim 1~~ claim 3, wherein the ~~macrolide compound~~ tricyclo compound of formula (I) is FK506




5. (Canceled)

6. (Presently Amended) The agent of ~~claim 5~~ claim 3, wherein the retinopathy is ischemic retinopathy.

7. (Presently Amended) The agent of claim 6, wherein the ischemic retinopathy is selected from the group consisting of diabetic retinopathy, fundus hypertonicus, central retinal artery occlusion, central retinal vein thrombosis, retinal peripheral vascular occlusion and retinopathy of prematurity.

8. (Presently Amended): The agent of ~~any of claim 1 to claim 7~~ claim 3, which is in the form of a preparation for local administration to the eye.

9. (Presently Amended): A method for treating retinopathy, ~~visual cell function disorder~~, comprising administering to a subject in need thereof an effective amount of ~~interleukin 2 inhibitor~~ an agent comprising a tricyclo compound of formula (I) of the following formula



wherein adjacent pairs of R<sup>1</sup> and R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup>, and R<sup>5</sup> and R<sup>6</sup> each independently

a) consist of two adjacent hydrogen atoms, wherein R<sup>2</sup> is optionally alkyl, or

b) form another bond optionally between carbon atoms binding with the members of

said pairs;

R<sup>7</sup> is hydrogen atom, hydroxy, protected hydroxy, or alkyloxy, or optionally form oxo with R<sup>1</sup>;

R<sup>8</sup> and R<sup>9</sup> are each independently a hydrogen atom or hydroxy;

R<sup>10</sup> is hydrogen atom, alkyl, alkyl substituted by one or more hydroxy, alkenyl, alkenyl substituted by one or more hydroxy or alkyl substituted by oxo;

X is oxo, (hydrogen atom, hydroxy), (hydrogen atom, hydrogen atom), or a group of the formula -CH<sub>2</sub>O-;

Y is oxo, (hydrogen atom, hydroxyl), (hydrogen atom, hydrogen atom), or a group of the formula N-NR<sup>11</sup>R<sup>12</sup> or N-OR<sup>13</sup>;

R<sup>11</sup> and R<sup>12</sup> are each independently a hydrogen atom, alkyl, aryl or tosyl;

R<sup>13</sup>, R<sup>14</sup>, R<sup>15</sup>, R<sup>16</sup>, R<sup>17</sup>, R<sup>18</sup>, R<sup>19</sup>, R<sup>22</sup> and R<sup>23</sup> are each independently a hydrogen atom or alkyl;

*Cont*  
*Any*  
R<sup>24</sup> is a ring that is optionally substituted and optionally contain one or more hetero atom(s); and


n is 1 or 2,

wherein Y, R<sup>10</sup> and R<sup>23</sup> are optionally, together with the carbon atom they bind with, a saturated or unsaturated 5 or 6-membered heterocyclic group containing nitrogen atom, sulfur atom and/or oxygen atom, the heterocyclic group being optionally substituted by one or more group(s) selected from the group consisting of alkyl, hydroxy, alkyloxy, benzyl, a group of the formula -CH<sub>2</sub>Se(C<sub>6</sub>H<sub>5</sub>), and alkyl substituted by one or more hydroxyl, or a pharmaceutically acceptable salt thereof,

~~to a subject in need of the treatment of retinopathy visual cell function disorder.~~

10. (Canceled)

11. (New) The method of claim 9, wherein the tricyclo compound of formula (I) is



12. (New) The method of claim 9, wherein the retinopathy is ischemic retinopathy.

13. (New) The method of claim 12, wherein the ischemic retinopathy is selected from the group consisting of diabetic retinopathy, fundus hypertonicus, central retinal artery occlusion, central retinal vein thrombosis, retinal peripheral vascular occlusion and retinopathy of prematurity.

Cont  
Apr 14

14. (New) The method of claim 9, wherein said administering is by local administration to the eye.

15. (New) The method of claim 14, wherein said effective amount is comprises 0.001 to 10 w/v% of the tricyclo compound of formula (I) administered 1 to 6 times per day.

16. (New) The method of claim 14, wherein said effective amount is comprises 0.005 to 5 w/v% of the tricyclo compound of formula (I) administered 1 to 6 times per day.

17. (New) The method of claim 9, wherein said effective amount is a dose ranging from 0.0001 to 1000 mg.

18. (New) The method of claim 17, wherein said dose is administered 2 to 4 times per day.

19. (New) The method of claim 9, wherein said effective amount is a dose ranging from 0.001 to 500 mg.

20. (New) The method of claim 19, wherein said dose is administered 2 to 4 times per day.

21. (New) The method of claim 9, wherein said agent further comprises one or more additives selected from the group consisting of an isotonizing agent, a buffer, a preservative, a tackifier, a hyaluronic acid or salt thereof, and a mucopolysaccharide.

22. (New) The agent of claim 3, wherein said agent further comprises one or more additives selected from the group consisting of an isotonizing agent, a buffer, a preservative, a tackifier, a hyaluronic acid or salt thereof, and a mucopolysaccharide.

---

SUPPORT FOR THE AMENDMENTS

Claims 1, 2, 5 and 10 have been canceled.

Claims 3, 4, and 6-9 have been amended.

Claims 11-22 have been added.

The amendment of Claims 3 is supported by Claims 3 and 5 as originally filed. The amendment of Claims 6 and 8 is supported by original Claim 1, 3, 5, 6, and 8. The amendment of Claim 4 is supported by original Claims 1, 3, and 4. The amendment of Claim 7 is supported by the specification page 11, lines 27-30. New Claims 11-14 are supported by page 2, line 4 to page 13, line 2. New Claims 15-22 are supported by page 12, line 8 to page 13, line 2.

No new matter is believed to have been entered by the present amendment.